Opioid Peptides Stimulate Rather Than Inhibit Cell Signaling in the Smell Center

In the olfactory bulb, opioid peptides stimulated adenylate cyclase by ~40% — the opposite of their usual inhibitory effect elsewhere in the brain — with beta-endorphin being most potent.

Onali, P et al.·Molecular pharmacology·1991·Preliminary Evidencein-vitro
RPEP-00204In VitroPreliminary Evidence1991RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

All three opioid peptides stimulated adenylate cyclase in olfactory bulb by ~40% above baseline. Beta-endorphin was most potent (EC50 22 nM). Naloxone blocked all effects.

Key Numbers

How They Did This

Rat olfactory bulb homogenates were treated with opioid peptides at various concentrations. Adenylate cyclase activity was measured. Naloxone antagonism confirmed receptor involvement.

Why This Research Matters

This finding challenges the assumption that opioid receptors always inhibit cell activity. In the olfactory bulb, they do the opposite, which could affect how we understand smell processing and opioid drug effects.

The Bigger Picture

This challenges the textbook view that opioid receptors always inhibit cells. In the smell center, they excite cells — which could affect how odors are processed and why certain smells trigger emotional or pain-related responses.

What This Study Doesn't Tell Us

In vitro study using tissue homogenates, which disrupts normal cellular context. Only one brain region examined. Rat findings may differ from humans.

Questions This Raises

  • ?Why do opioid receptors stimulate in the olfactory bulb but inhibit elsewhere?
  • ?Do opioid drugs affect sense of smell?

Trust & Context

Key Stat:
~40% stimulation (not inhibition) Opioid peptides had the opposite effect in the olfactory bulb compared to most other brain regions
Evidence Grade:
Preliminary in-vitro study using tissue homogenates. The stimulatory effect is clear but the mechanism needs further investigation.
Study Age:
Published in 1991. Region-specific opioid receptor coupling is now better understood.
Original Title:
Naturally occurring opioid receptor agonists stimulate adenylate cyclase activity in rat olfactory bulb.
Published In:
Molecular pharmacology, 39(4), 436-41 (1991)
Authors:
Onali, P(2), Olianas, M C(2)
Database ID:
RPEP-00204

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

How can the same receptor do opposite things in different brain regions?

Opioid receptors can couple to different G-proteins depending on the cell type. In most neurons, they couple to inhibitory G-proteins. In the olfactory bulb, they appear to couple to stimulatory G-proteins — completely changing the effect.

Could this affect how pain patients experience smell?

Possibly. Since opioid medications affect opioid receptors throughout the brain including the olfactory bulb, they could alter smell perception — though this hasn't been systematically studied.

Read More on RethinkPeptides

Cite This Study

RPEP-00204·https://rethinkpeptides.com/research/RPEP-00204

APA

Onali, P; Olianas, M C. (1991). Naturally occurring opioid receptor agonists stimulate adenylate cyclase activity in rat olfactory bulb.. Molecular pharmacology, 39(4), 436-41.

MLA

Onali, P, et al. "Naturally occurring opioid receptor agonists stimulate adenylate cyclase activity in rat olfactory bulb.." Molecular pharmacology, 1991.

RethinkPeptides

RethinkPeptides Research Database. "Naturally occurring opioid receptor agonists stimulate adeny..." RPEP-00204. Retrieved from https://rethinkpeptides.com/research/onali-1991-naturally-occurring-opioid-receptor

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.